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Abstract
Interest in the use of cardiac troponin T (cTnT) and cardiac troponin I (cTnI) has expanded from diagnosis of acute myocardial
infarction to risk assessment for morbidity and mortality. Although cTnT and cTnI were shown to have equivalent diagnostic
performance in the setting of suspected acute myocardial infarction, potential prognostic differences are largely unexplored.
The aim of this study is to quantify and compare the relationship between cTnT and cTnI, and cardiovascular and all-cause
mortality in the general population.
Medline, Embase, and the Cochrane Library (from inception through October 2016) were searched for prospective observational
cohort studies reporting on the prognostic value of basal high-sensitive cTnT and/or cTnI levels on cardiovascular and all-cause
mortality in the general population. Data on study characteristics, participants’ characteristics, outcome parameters, and quality
[according to the Effective Public Health Practice Project (EPHPP) “Quality Assessment Tool For Quantitative Studies] were retrieved.
Hazard ratios per standard deviation increase in basal cardiac troponin level (HR per 1-SD; retrieved from the included articles or
estimated) were pooled using a random-effects model.
On a total of 2585 reviewed citations, 11 studies, with data on 65,019 participants, were included in the meta-analysis. Random
effects pooling showed signiﬁcant associations between basal cardiac troponin levels and HR for cardiovascular and all-cause
mortality [HR per 1-SD 1.29 (95% conﬁdence interval, 95% CI, 1.20–1.38) and HR per 1-SD 1.18 (95% CI, 1.11–1.26), respectively].
Stratiﬁed analyses showed higher HRs for cTnT than cTnI [cardiovascular mortality: cTnT HR per 1-SD 1.37 (95%CI, 1.23–1.52); and
cTnI HR per 1-SD 1.21 (95% CI, 1.16–1.26); all-cause mortality: cTnT HR per 1-SD 1.31 (955 CI, 1.13–1.53); and cTnI HR per 1-SD
1.14 (95% CI, 1.06–1.22)]. These differences were signiﬁcant (P<0.01) in meta-regression analyses for cardiovascular mortality but
did not reach statistical signiﬁcance for all-cause mortality.
Elevated, basal cTnT, and cTnI show robust associations with an increased risk of cardiovascular and all-cause mortality during
follow-up in the general population.
Systematic review registration number PROSPERO CRD42014006964.
Abbreviations: cTnI = cardiac troponin I, cTnT = cardiac troponin T, HR = hazard ratio, NSTEMI = non-ST elevated myocardial
infarction, SD = standard deviation.
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11. Introduction
Cardiac troponins are the preferred biomarkers in the diagnostic
work up for non-ST elevation myocardial infarction
(NSTEMI).[1,2] Troponin assays target either cardiac troponin
T or cardiac troponin I, both sarcomere components of the
heart.[3] The release of cardiac troponin in the peripheral blood is
strongly associated with myocardial injury.[4] The recent
introduction of high-sensitive cardiac troponin assays has not
only expedited the early diagnosis of NSTEMI but also resulted in
the detection of previously unnoticed cardiac troponin levels in
various patient groups without acute cardiac injury such as
chronic kidney disease, chronic heart failure, and even in
apparently healthy subjects.[5,6] Subsequently, several studies
have shown that even these minimal increases of cardiac troponin
T and I are associated with unfavorable outcomes in various
patient groups.[6–10]
The current guidelines recommend either cardiac troponin T
and I for de diagnosis of acute myocardial infarction, suggesting
equivalent diagnostic performance of troponin T and I in the
acute situation.[11] In contrast, cardiac troponin T seems to have
van der Linden et al. Medicine (2016) 95:52 Medicinegreater prognostic accuracy than cardiac troponin I in the acute
setting.[12] Potential differences in prognostic value between basal
cardiac troponin T and I concentrations in subjects from the
general population are largely unexplored. In addition, the
quantitative relationship between elevated cardiac troponin
levels, also below the 99th percentile, and the magnitude of risk
for adverse events has not been systematically assessed.
To address these knowledge gaps, we conducted a systematic
review and meta-analysis of the available evidence from
published prospective cohort studies. Speciﬁcally, we quantiﬁed
the relationship between basal levels of high-sensitive cardiac
troponins and cardiovascular and all-cause mortality during
follow-up in the general population. In addition, the prognostic
performance of high-sensitive cardiac troponin T and I assays
was separately assessed and compared.2. Methods
2.1. Data sources and searches
Medline, Embase, and the Cochrane Library were searched
from inception through October 2016. Also, the reference lists
of all relevant articles and Web of Science (for prospective
citations of key publications) were checked for any additional
articles. The PubMed search terms were (mortality OR death
OR “Mortality”[Mesh]) AND (troponin OR “Troponin”[-
Mesh]) AND (predictive OR prediction OR prognostic OR
prognosis OR “Prognosis”[Mesh] risk OR “Risk”[Mesh]) AND
(follow-up OR prospective OR cohort). We adapted this search
strategy for searches of Embase and the Cochrane Library. The
search was restricted to English, Dutch, French, and German
documents.
The protocol for this study was published on the International
Prospective Register of Systematic Reviews, or PROSPERO. The
registration number was CRD42014006964. Due to the design
of the present study, ethical approval was not required. All
included studies were approved by the notiﬁed ethics committees
and institutional review boards.2.2. Study selection
Study selection was performed by 2 independent investigators
(NvdL and LK). We included all prospective cohort studies that
evaluated the prognostic value of basal high-sensitive cardiac
troponin T and I levels in subjects from the general population
(without any suspected acute event or surgery at the time of
sampling) for cardiovascular and all-cause mortality during
follow-up.
Studies were excluded from the meta-analysis when the
duration of follow-up was less than 1 year, hazard ratios
(HRs) for cardiovascular or all-cause mortality were not
provided [either as HR per stratum, or as HR per 1-standard
deviation (SD) increase in logarithmic transformed cardiac
troponin concentrations], or when HRs were not adjusted for
conventional cardiovascular risk factors [at least for age, sex,
smoking, hypertension (or systolic blood pressure), diabetes
mellitus (or glucose levels), and dyslipidemia (or levels of total
and high-density lipoprotein, HDL cholesterol)]. When duplicate
publications of data were encountered, only results from the most
recent publication were considered. Discrepancies between
reviewers were resolved in the presence of a third reviewer
(SM). All authors that performed search and selection were
trained in systematic review and meta-analysis methods.22.3. Data extraction and quality assessment
We extracted data using a customized and validated extraction
form. Data on study characteristics (authors, publication year,
journal, study design, sample size, country, and duration of
follow-up), participants’ characteristics [age, sex, history of
cardiovascular disease (CVD), hypertension, dyslipidemia,
diabetes], cardiovascular and all-cause mortality rate, cardiac
troponin assay, HRs for cardiovascular, and all-cause mortality,
the factors for which the HRs had been adjusted for, and C-
statistics and reclassiﬁcation were retrieved. When multiple
cardiac troponin assays of the same kind (cardiac troponin I or T)
were presented, we used the data from the assay that was
commercially available and most commonly used in clinical
practice for our analyses. Two authors (NvdL and LK) performed
the data-extraction separately. Discrepancies between reviewers
were resolved in THE presence of a third reviewer (SM).
To assess study quality, each study was evaluated for selection
bias, study design, confounders, blinding, data collection
methods, and withdrawals/dropouts according to the Effective
Public Health Practice Project (EPHPP) “Quality Assessment
Tool For Quantitative Studies.”[13] Two authors (NvdL and LK)
performed quality assessment separately, and disagreements were
resolved by consensus in the presence of a third review author
(SM)2.4. Data synthesis and analysis
To quantitatively assess the relationship between basal cardiac
troponin levels and cardiovascular and all-cause mortality during
follow-up, we used HR per 1-SD increase in logarithmic
transformed cardiac troponin levels. When HRs were provided
for stratiﬁed cardiac troponin concentrations only, we mathe-
matically derived HR per 1-SD increase in logarithmic trans-
formed cardiac troponin concentration. This estimation was
based on the assumption that logarithmic transformed cardiac
troponin levels are normally distributed in the population,[14–16]
and consisted of the following 3 steps: we extracted the
cumulative distribution of the study population and calculated
the associated z-scores on the basis of the cumulative standard
normal distribution, we calculated the mean and SD based on the
z-scores [z= (x-m)/s, where x is the log-transformed cardiac
troponin concentration acting as the upper limit of the stratum
(continuity correction was performed), m is the mean, and s is the
SD], and we constructed a biomarker concentration-risk curve
(x-axis: log-transformedmedians for the strata, y-axis: associated
HRs) for which we calculated the slope (HR/log cardiac
troponin) and transformed this into HR per 1-SD increase in
logarithmic transformed cardiac troponin level. This method was
validated in 2 studies that reported HRs for both stratiﬁed data
and log-transformed cardiac troponin as a continuous vari-
able.[17,18] We found a minimal differences between the reported
and the calculated HR per 1-SD in these 2 studies (2–8%
difference).
For the meta-analysis, we used full-model adjusted HRs [at
least adjusted for the conventional cardiovascular risk factors
age, sex, smoking, hypertension (or systolic blood pressure),
diabetes mellitus (or glucose levels), and dyslipidemia (or levels of
total and HDL cholesterol]. As a result of this approach, the
number of adjusting factors in the full-model differs between
studies. Nevertheless, this method ensures that we correct for all
signiﬁcant confounders in the individual studies. As cardiac
troponins are strongly associated with CVD, the set of adjusting
van der Linden et al. Medicine (2016) 95:52 www.md-journal.comfactors mainly consists of cardiovascular risk factors. The
adjusted HRs per 1-SD were pooled using a random-effects
model and summarized using forest plots.
Examination of the impact of potential moderator variables on
the study effect size was done by meta-regression analyses.
Potential moderator variables included type of cardiac troponin
assay, calculated versus reported HRs, study quality, geographic
region, andmean age of the population. A sensitivity analysis was
applied to examine the effect of the inclusion of studies, which did
not adjust for the minimal set of 6 conventional risk factors, on
the robustness of the pooled results.
The MOOSE guidelines[19] for meta-analysis of observational
studies were followed, and PRISMA criteria were performed for
the search methodology (Fig. 1). Publication bias was evaluated
using Egger regression. Heterogeneity between studies was
estimated using I2.[20]
For all analyses, a 2-tailed P value less than 0.05was considered
statistically signiﬁcant. All statistical analyseswere performedwith
the Stata software package (Stata/IC version 13.1; Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP).
3. Results
3.1. Study characteristics
The literature search protocol is depicted in Fig. 1. Our initial
search identiﬁed 2585 citations. On the basis of titles and
abstracts, 41 articles were considered potentially eligible. After
full text evaluation, 29 articles were excluded: 8 articles did not
report HRs for high-sensitive cardiac troponin concentrationsFigure 1. Flow chart of
3and survival, 7 did not perform a survival analysis, 4 did not
report on cardiovascular or all-cause mortality as outcome
measures, 2 were not performed in the general population, and 6
articles reported data that were also published in more recent
articles. In 2 studies, the reported HRs were not adjusted for the
minimal list of conventional risk factors. As the adjustment for
these factors is one of the inclusion criteria, those studies were
excluded. Hence, a total of 11 studies (12 articles) (65,019
participants) were eventually included in the meta-analysis; 7
studies (45,956 participants) for cardiovascular
mortality[15,17,21–25] and 10 studies (48,679 participants) for
all-cause mortality.[15,17,18,22–24,26–29] Five studies reported HRs
related to cardiac troponin T levels,[17,18,21–23,26] and another 5
studies reported on cardiac troponin I levels.[15,24,25,27–29]
Clinical and demographic characteristics are summarized in
Table 1. The median follow-up duration of all studies was
between 3.8 and 20 years. The percentage of individuals with
detectable cardiac troponin levels varied from 27% to 96%.
The study quality varied across studies. According to the
EPHPP quality assessment tool,[13] 1 study was of high
methodological quality,[27] 8 studies were of moderate
quality,[17,18,21–25,28,29] and 2 studies were of lowmethodological
quality.[15,26] The global rating “weak” for study quality was due
to lack of information about subject inclusion, study with-
drawals, and dropouts. To ascertain vital status, studies used
death registries (n=5),[17,22,24,26,29] medical records (n=
3),[18,21,27,28] the combination of medical records and death
registries (n=2),[15,25] and the combination of interviews,
medical records, and a death register (n=1).[23] All includedthe study selection.
van der Linden et al. Medicine (2016) 95:52 Medicinestudies provided HRs adjusted for at least 6 conventional
cardiovascular risk factors, described in the Methods section.
Quality assessment scores and additional adjustments made by
the individual studies are presented in Supplemental Table S1,
http://links.lww.com/MD/B481.3.2. Association between cardiac troponin concentration
and mortality
We pooled adjusted HRs per 1-SD for all studies using a random-
effects model. Pooling of the results from the 7 included studies
for cardiovascular mortality showed a signiﬁcant association
between increased basal cardiac troponin levels and an elevated
HR for cardiovascular mortality (HR per 1-SD 1.29, 95%Figure 2. Association between 1 standard deviation increase in basal cardiac trop
population. The boxes and lines in the forest plots indicate the hazard ratio for car
troponin concentrations for individual studies and a pooled estimate (random-effec
studies on cardiac troponin I (panel C).
4conﬁdence interval, 95%CI, 1.20–1.38). Cardiac troponin Twas
signiﬁcantly stronger associated with cardiovascular mortality
than with cardiac troponin I (meta-regression analysis P<0.01;
HR per 1-SD 1.37, 95% CI 1.23–1.52 and HR per 1-SD 1.21,
95% CI 1.16–1.26, for cardiac troponin T and I, respectively).
The forest plots of the random-effects pooled data for all-cause
mortality are shown in Fig. 2.
Pooling of the results from the nine included studies for all-
cause mortality showed a signiﬁcant association between
increased basal cardiac troponin levels and an elevated HR for
all-cause mortality (HR per 1-SD 1.18, 95% CI 1.11–1.26).
Considering the trend toward different effect sizes (HR per 1-SD)
for cardiac troponin T and I shown by meta-regression analysis
(P=0.09), we performed stratiﬁed analyses for both isoforms ofonin concentrations and hazard ratio for cardiovascular mortality in the general
diovascular mortality per standard deviation increase (HR per 1-SD) in cardiac
ts model) for all studies (panel A), studies on cardiac troponin T (panel B), and
van der Linden et al. Medicine (2016) 95:52 www.md-journal.comcardiac troponin. Basal cardiac troponin T levels translated to a
higher HR for all-cause mortality [(HR per 1-SD 1.31, 95% CI
1.13–1.53) vs (HR per 1-SD 1.14, 95% CI 1.06–1.22)]. The
forest plots of the random-effects pooled data for all-cause
mortality are shown in Fig. 3.
3.3. Heterogeneity and publication bias assessment
Our meta-analysis revealed substantial heterogeneity across
studies (Figs. 2–3). We used meta-regression analyses to identifyFigure 3. Association between 1 standard deviation increase in basal cardiac t
population. The boxes and lines in the forest plots indicate the hazard ratio for all-ca
concentrations for individual studies and a pooled estimate (random-effects model
cardiac troponin I (panel C).
5the underlying factors. Univariable meta-regression analyses
pointed out that estimated versus reported HR and study quality
(strong/moderate vs weak global rating) were not statistically
signiﬁcant predictors, whereas the assay-type (high-sensitive
cardiac troponin T or I) was statistically signiﬁcant for
cardiovascular mortality (P<0.01) but did not reach signiﬁcance
for all-cause mortality (P=0.09). Besides, age was a borderline
signiﬁcant factor in meta-regression analysis for cardiac troponin
I and all-cause mortality (P=0.05), indicating that older age isroponin concentrations and hazard ratio for all-cause mortality in the general
use mortality per standard deviation increase (HR per 1-SD) in cardiac troponin
) for all studies (panel A), studies on cardiac troponin T (panel B), and studies on
van der Linden et al. Medicine (2016) 95:52 Medicineassociated with a stronger correlation between troponin
concentration and risk.
One SD increase in basal cardiac troponin T levels was
associated with a higher HR for cardiovascular and all-cause
mortality during follow-up than a similar increase in troponin I.
Stratiﬁed analyses for cardiac troponin T and I decreased
heterogeneity across troponin T studies (I2=37.9%, P=0.18 and
I2=62.7%, P=0.03, for cardiovascular and all-cause mortality,
respectively). Across studies with cardiac troponin I, heterogene-
ity for cardiovascular mortality decreased (I2=0.0%, P=0.40),
but remained high for all-cause mortality (I2=83.4%, P<0.01).
Egger regression analysis was not indicative for publication
bias (P=0.50 and P=0.68, for cardiovascular and all-causeFigure 4. Cardiac troponin levels and corresponding hazard ratios. HR per 1-SD
corresponding hazard ratios for all high-sensitive troponin assays that were inclu
6mortality, respectively) (Supplemental Figure 1 and 2, http://
links.lww.com/MD/B481).3.4. Sensitivity analysis
For all-cause mortality, 2 studies were excluded because they did
not correct for at least the 6 conventional cardiovascular risk
factors. To verify that pooled HRs were robust and independent,
a sensitivity analysis including those 2 studies was performed.
Random-effects pooling after the addition of 2 additional
studies[30,31] revealed similar results regarding all-cause mortality
and reduced heterogeneity for cardiac troponin T [HR per 1-SD
1.30, 95% CI 1.16–1.47; I2=52.9% (P=0.060)], cardiacincrease was transformed to absolute cardiac troponin concentrations and
ded in the meta-analysis.
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van der Linden et al. Medicine (2016) 95:52 Medicinetroponin I [HR per 1-SD 1.14, 95% CI 1.07–1.22; I =79.3%
(P<0.01)], and the combined analysis [HR per 1-SD 1.19, 95%
CI 1.12–1.26; I2=71.3% (P<0.01)]. The meta-regression
analysis that was performed after the inclusion of 2 additional
studies[30,31] showed a signiﬁcant effect of assay-type (cardiac
troponin T vs I) on the observed heterogeneity (P=0.05).3.5. Translation to clinical practice
Together, the pooled data show that elevated basal cardiac
troponin levels in the general population are associated with
increased mortality during follow-up and suggest a slightly
stronger association for cardiac troponin T than for cardiac
troponin I. To relate the pooled summary measures per SD, to a
clinically comprehensible risk estimation tool, we transformed
HR per 1-SD to absolute cardiac troponin concentrations and
corresponding HRs for all high-sensitive troponin assays that
were included in the meta-analysis. Figure 4 depicts the relation
between basal cardiac troponin T and I concentrations and
mortality during follow-up.
The majority of included studies performed discrimination and
reclassiﬁcation statistics (Supplemental Table S2, http://links.
lww.com/MD/B481).[15,17,21,22,24,25,27,29] The results from these
analyses suggest small, but signiﬁcant improvements in (estab-
lished) prediction models based on established risk factors after
the inclusion of high-sensitive cardiac troponin T or I.4. Discussion
This meta-analysis with data on 65,019 participants from 11
prospective cohorts shows that basal elevated cardiac troponin
concentrations, also below the 99th percentile, in the general
population are associated with an increased risk for cardiovas-
cular and all-cause mortality during follow-up. The pooled data
analyses corroborate and extend the ﬁndings of previous
studies.[7–9,32,33] Besides, our results suggest that the quantita-
tive relationship between cardiac troponin concentrations is
stronger for cardiovascular than for all-cause mortality, and
may be slightly stronger for cardiac troponin T than for cardiac
troponin I.
The observed association between elevated cardiac troponin
concentrations and an increased risk for cardiovascular mortality
and, to a lesser extent, for all-cause mortality, are reﬂected in the
discrimination and reclassiﬁcation statistics of the included
studies. These analyses indicate that the addition of cardiac
troponins may cause a small, but signiﬁcant improvement in risk
prediction models.[15,17,21,22,24,25,27,29] Some recent studies, but
not all, suggest that the addition of cardiac troponin I to existing
risk prediction models may be particularly useful among a
subpopulation, especially in older and female subjects.[24,25,29,33]
Before cardiac troponins can be actually implemented in clinical
practice, it is necessary to identify the suitable target population
and the best combination of biomarkers for risk prediction, also
from a cost-effectiveness point of view.
The observed differences in the quantitative relationships of
high-sensitive cardiac troponin T and I are clinically and
scholarly interesting, and contrast with demonstrated equivalent
performance of both assays in the acute setting, that is, for
diagnosing acute myocardial infarction.[34] We can only
speculate about the factors that might underlie these apparent
prognostic differences. A ﬁrst factor concerns the analytical
aspects of the distinct cardiac troponin assays. It is conceivable
that intrinsic assay differences, including the use of different8antibodies, may affect distinctive power of troponin assays
with direct consequences for prognostic performance. A second
factor involves the release of cardiac troponins. The mechanism
of chronic cardiac troponin release is not elucidated, but recent
observations suggest differences in release patterns of cardiac
troponin T and I.[36] Third, postrelease modiﬁcation such as
fragmentation, complex formation, and elimination of cardiac
troponins may differ between both cardiac troponins.[37,38]
This meta-analysis has several strengths, including its large
patient populations, standardization of the outcome measure,
and the comparison of cardiac troponin T and I. Limitations of
our study merit consideration: First, despite the consistent
adjustment for at least 6 established cardiovascular risk factors
and the use of a standardized outcome measure (HR per 1-SD),
heterogeneity was substantial, which persisted in assay-stratiﬁed
analyses, in particular across all-cause mortality studies. Meta-
regression analyses did not identify other suggestive factors that
contributed to heterogeneity. A likely, remaining source of
heterogeneity is the diversity in populations, caused by variable
in- and exclusion criteria of the individual studies. Nonetheless,
despite the detected heterogeneity, all studies revealed the same
direction of effect, with increased mortality upon higher levels of
circulating cardiac troponin. Second, due to the fact that we did
not have access to the individual, data and that the percentage of
included women showed minimal variation, we were unable to
examine the effect of gender. Therefore, we cannot conﬁrm
that gender affects the relation between cardiac troponin
concentrations and the risk on cardiovascular and all-cause
mortality.[24,30,33] With respect to age, we could only examine the
effect of the mean age across the included studies. In line with
previous observations,[33] we found a borderline signiﬁcant
association between increasing age and a stronger correlation
between troponin I and all-cause mortality. We cannot exclude
that the variation in in- and exclusion criteria and adjusting
factors might have masked a more explicit effect of age. Third,
HR per 1-SD from stratiﬁed data has been mathematically
derived. However, validation of this method in 2 studies revealed
minimal discrepancies, and this approach to standardize risk-
estimates enabled us to pool rather heterogeneously presented
data, and to perform a meta-analysis with substantial statistical
power and long-term follow-up. Fourth, the measurement and
deﬁnition of mortality outcomes differs across studies. The
deﬁnition of cardiovascular mortality varied slightly across
studies, but in general, it concerned the ICD-10 diagnosis I00-I99.5. Conclusion
Elevated, basal cardiac troponin T and I levels are signiﬁcantly
associated with an increased risk of cardiovascular and all-cause
mortality during follow-up in the general population. The results
of this meta-analysis suggest that this association is stronger for
cardiovascular than for all-cause mortality. The observation that
the quantitative relationship between cardiac troponin concen-
tration and mortality risk may be stronger for cardiac troponin T
than for cardiac troponin I is an interesting ﬁnding that requires
further research. In addition, future studies should focus on
further establishment and validation of cardiac troponins for the
prediction of long-term outcomes.References
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